Information Provided By: 
Fly News Breaks for December 28, 2017
ANIK
Dec 28, 2017 | 09:20 EDT
Barrington analyst Michael Petusky said he does not see Anika Therapeutics' HA-based bone void filler, which just received FDA clearance, to contribute materially to 2018 revenues, but he does view the clearance as another positive step in the company's path toward building out a meaningful regenerative medicine franchise. He keeps an Outperform rating and $57 price target on Anika shares.
News For ANIK From the Last 2 Days
There are no results for your query ANIK
